IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0221856.html
   My bibliography  Save this article

Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review

Author

Listed:
  • Alexander V van Schoonhoven
  • Judith J Gout-Zwart
  • Marijke J S de Vries
  • Antoinette D I van Asselt
  • Evgeni Dvortsin
  • Pepijn Vemer
  • Job F M van Boven
  • Maarten J Postma

Abstract

Background: Type 2 diabetes mellitus (T2DM) is an established risk factor for cardiovascular and nephropathic events. In the Netherlands, prevalence of T2DM is expected to be as high as 8% by 2025. This will result in significant clinical and economic impact, highlighting the need for well-informed reimbursement decisions for new treatments. However, availability and consistent use of costing methodologies is limited. Objective: We aimed to systematically review recent costing data for T2DM-related cardiovascular and nephropathic events in the Netherlands. Methods: A systematic literature review in PubMed and Embase was conducted to identify available Dutch cost data for T2DM-related events, published in the last decade. Information extracted included costs, source, study population, and costing perspective. Finally, papers were evaluated using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS). Results: Out of initially 570 papers, 36 agreed with the inclusion criteria. From these studies, 150 cost estimates for T2DM-related clinical events were identified. In total, 29 cost estimates were reported for myocardial infarction (range: €196-€27,038), 61 for stroke (€495-€54,678), fifteen for heart failure (€325-€16,561), 24 for renal failure (€2,438-€91,503), and seventeen for revascularisation (€3,000-€37,071). Only four estimates for transient ischaemic attack were available, ranging from €587 to €2,470. Adherence to CHEERS was generally high. Conclusions: The most expensive clinical events were related to renal failure, while TIA was the least expensive event. Generally, there was substantial variation in reported cost estimates for T2DM-related events. Costing of clinical events should be improved and preferably standardised, as accurate and consistent results in economic models are desired.

Suggested Citation

  • Alexander V van Schoonhoven & Judith J Gout-Zwart & Marijke J S de Vries & Antoinette D I van Asselt & Evgeni Dvortsin & Pepijn Vemer & Job F M van Boven & Maarten J Postma, 2019. "Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review," PLOS ONE, Public Library of Science, vol. 14(9), pages 1-22, September.
    • Handle: RePEc:plo:pone00:0221856
    DOI: 10.1371/journal.pone.0221856
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0221856
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0221856&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0221856?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Don Husereau & Michael Drummond & Stavros Petrou & Chris Carswell & David Moher & Dan Greenberg & Federico Augustovski & Andrew Briggs & Josephine Mauskopf & Elizabeth Loder, 2013. "Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(3), pages 367-372, June.
    2. Tamara Schmid, 2015. "Costs of treating cardiovascular events in Germany: a systematic literature review," Health Economics Review, Springer, vol. 5(1), pages 1-11, December.
    3. van Os, Nicole & Niessen, Louis W. & Bilo, Henk J. G. & Casparie, Anton F. & van Hout, Ben A., 2000. "Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines," Health Policy, Elsevier, vol. 51(3), pages 135-147, April.
    4. S. Tan & F. Rutten & B. Ineveld & W. Redekop & L. Hakkaart-van Roijen, 2009. "Comparing methodologies for the cost estimation of hospital services," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 10(1), pages 39-45, February.
    5. de Wit, G.Ardine & Ramsteijn, Paul G & de Charro, Frank Th, 1998. "Economic evaluation of end stage renal disease treatment," Health Policy, Elsevier, vol. 44(3), pages 215-232, June.
    6. Bart Heeg & Ron Peters & Marc Botteman & Ben Hout, 2007. "Long-Term Clopidogrel Therapy in Patients Receiving Percutaneous Coronary Intervention," PharmacoEconomics, Springer, vol. 25(9), pages 769-782, September.
    7. Jelena Stevanović & Marjolein Pompen & Hoa H Le & Mark H Rozenbaum & Robert G Tieleman & Maarten J Postma, 2014. "Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands," PLOS ONE, Public Library of Science, vol. 9(8), pages 1-11, August.
    8. J. Oostenbrink & F. Rutten, 2006. "Cost assessment and price setting of inpatient care in the Netherlands. The DBC case-mix system," Health Care Management Science, Springer, vol. 9(3), pages 287-294, August.
    9. Lisa Ericson & Lennart Bergfeldt & Ingela Björholt, 2011. "Atrial fibrillation: the cost of illness in Sweden," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(5), pages 479-487, October.
    10. David Moher & Alessandro Liberati & Jennifer Tetzlaff & Douglas G Altman & The PRISMA Group, 2009. "Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement," PLOS Medicine, Public Library of Science, vol. 6(7), pages 1-6, July.
    11. Martine Bellanger & Wilm Quentin & Siok Swan Tan, 2013. "Childbirth and Diagnosis Related Groups (DRGs): patient classification and hospital reimbursement in 11 European countries," Post-Print hal-01505629, HAL.
    12. Voss, Gemma B. W. E. & Hasman, Arie & Rutten, Frans & de Zwaan, Chris & Carpay, Jan J., 1994. "Explaining cost variations in DRGs `Acute Myocardial Infarction' by severity of illness," Health Policy, Elsevier, vol. 28(1), pages 37-50, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Thomas Grochtdreis & Hans-Helmut König & Alexander Dobruschkin & Gunhild von Amsberg & Judith Dams, 2018. "Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review," PLOS ONE, Public Library of Science, vol. 13(12), pages 1-25, December.
    2. Neily Zakiyah & Antoinette D I van Asselt & Frank Roijmans & Maarten J Postma, 2016. "Economic Evaluation of Family Planning Interventions in Low and Middle Income Countries; A Systematic Review," PLOS ONE, Public Library of Science, vol. 11(12), pages 1-19, December.
    3. Boshen Jiao & Anirban Basu & Joshua Roth & M. Bender & Ilsa Rovira & Traci Clemons & Dalyna Quach & Scott Ramsey & Beth Devine, 2021. "The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature," PharmacoEconomics, Springer, vol. 39(11), pages 1225-1241, November.
    4. Huajie Jin & Paul Tappenden & Stewart Robinson & Evanthia Achilla & David Aceituno & Sarah Byford, 2020. "Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia," PLOS ONE, Public Library of Science, vol. 15(7), pages 1-18, July.
    5. Holger Möller & Fiona Haigh & Rema Hayek & Lennert Veerman, 2020. "What Is the Best Practice Method for Quantifying the Health and Economic Benefits of Active Transport?," IJERPH, MDPI, vol. 17(17), pages 1-16, August.
    6. S. Rajsic & H. Gothe & H. H. Borba & G. Sroczynski & J. Vujicic & T. Toell & Uwe Siebert, 2019. "Economic burden of stroke: a systematic review on post-stroke care," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 107-134, February.
    7. Finkelstein, Eric A. & Bilger, Marcel & Baid, Drishti, 2019. "Effectiveness and cost-effectiveness of incentives as a tool for prevention of non-communicable diseases: A systematic review," Social Science & Medicine, Elsevier, vol. 232(C), pages 340-350.
    8. Darcy M. Anderson & Ryan Cronk & Donald Fejfar & Emily Pak & Michelle Cawley & Jamie Bartram, 2021. "Safe Healthcare Facilities: A Systematic Review on the Costs of Establishing and Maintaining Environmental Health in Facilities in Low- and Middle-Income Countries," IJERPH, MDPI, vol. 18(2), pages 1-22, January.
    9. Raulinajtys-Grzybek, Monika, 2014. "Cost accounting models used for price-setting of health services: An international review," Health Policy, Elsevier, vol. 118(3), pages 341-353.
    10. Susanne Mayer & Noemi Kiss & Agata Łaszewska & Judit Simon, 2017. "Costing evidence for health care decision-making in Austria: A systematic review," PLOS ONE, Public Library of Science, vol. 12(8), pages 1-18, August.
    11. Zuzana Špacírová & David Epstein & Leticia García-Mochón & Joan Rovira & Antonio Olry de Labry Lima & Jaime Espín, 2020. "A general framework for classifying costing methods for economic evaluation of health care," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(4), pages 529-542, June.
    12. Joan Mendivil & Marilena Appierto & Susana Aceituno & Mercè Comas & Montserrat Rué, 2019. "Economic evaluations of screening strategies for the early detection of colorectal cancer in the average-risk population: A systematic literature review," PLOS ONE, Public Library of Science, vol. 14(12), pages 1-18, December.
    13. Nikita M. John & Stuart J. Wright & Sean P. Gavan & Caroline M. Vass, 2019. "The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(8), pages 1123-1131, November.
    14. Daniel M. Sugrue & Thomas Ward & Sukhvir Rai & Phil McEwan & Heleen G. M. Haalen, 2019. "Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design," PharmacoEconomics, Springer, vol. 37(12), pages 1451-1468, December.
    15. Christian Kromer & Daniel Celis & Diana Sonntag & Wiebke K Peitsch, 2018. "Biologicals and small molecules in psoriasis: A systematic review of economic evaluations," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-22, January.
    16. Chiranjeev Sanyal & Paul Stolee & Don Juzwishin & Don Husereau, 2018. "Economic evaluations of eHealth technologies: A systematic review," PLOS ONE, Public Library of Science, vol. 13(6), pages 1-11, June.
    17. Habibollah Arefian & Monique Vogel & Anja Kwetkat & Michael Hartmann, 2016. "Economic Evaluation of Interventions for Prevention of Hospital Acquired Infections: A Systematic Review," PLOS ONE, Public Library of Science, vol. 11(1), pages 1-15, January.
    18. Brigid M Gillespie & Claudia Bull & Rachel Walker & Frances Lin & Shelley Roberts & Wendy Chaboyer, 2018. "Quality appraisal of clinical guidelines for surgical site infection prevention: A systematic review," PLOS ONE, Public Library of Science, vol. 13(9), pages 1-17, September.
    19. Stephen Mac & Sara R da Silva & Beate Sander, 2019. "The economic burden of Lyme disease and the cost-effectiveness of Lyme disease interventions: A scoping review," PLOS ONE, Public Library of Science, vol. 14(1), pages 1-17, January.
    20. Wolf Rogowski & Wolfram Elsner, 2021. "How economics can help mitigate climate change - a critical review and conceptual analysis of economic paradigms," Bremen Papers on Economics & Innovation 2106, University of Bremen, Faculty of Business Studies and Economics.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0221856. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.